Jazz Pharmaceuticals has agreed to acquire the speciality oncology company EUSA Pharma in an all-cash deal worth up to US$700 M. The key driver of the deal is EUSA’s orphan cancer drug Erwinaze™ (asparaginase Erwinia chrysanthemi), which was approved by the US FDA in November 2011 for paediatric acute lymphoblastic leukaemia. The deal is expected to add US$210–230 M to Jazz’s 2013 revenues.